Abstract

Crinetics Pharmaceuticals Inc. will report its quarterly results on February 26, 2026 Post Market; this preview summarizes recent operating trends, consensus forecasts for revenue, EBIT, EPS, and margins, and collates institutional sentiment and rating changes since January 1, 2026.

Market Forecast

Based on the company’s latest guidance set and market tracking, Crinetics Pharmaceuticals Inc. is expected this quarter to post revenue of $4.74 million with an estimated year-over-year increase of 555%; the forecast implies EBIT of -$133.09 million and EPS of -$1.37, where EPS is expected to decline by 53.83% year-over-year and EBIT to decline by 52.04% year-over-year. Forecast margin specifics have not been provided, though the implied trajectory suggests ongoing operating losses while the topline benefits from recognized collaboration and license revenue. The company’s main business currently centers on license revenue recognition, with the highlight being a projected pickup in recognized licensing payments that sustains cash runway despite ongoing R&D spend; the segment with the largest near-term potential is authorized licensing revenue, projected at $4.74 million this quarter, up 555% year-over-year.

Last Quarter Review

Crinetics Pharmaceuticals Inc. last quarter recorded revenue of $0.14 million, a GAAP net loss attributable to the parent company of $13.00 million with a quarter-on-quarter change of -12.50%, and adjusted EPS of -$1.38; gross margin and net margin were not disclosed in the returned dataset. The quarter’s key operational highlight was the recognition of $0.46 million in license fees, which, while modest, demonstrates the company’s accounting recognition of non-recurring revenue streams amid clinical-stage R&D spending. By business, recognized license revenue was $0.46 million, with reported year-over-year dynamics not specified in the dataset.

Current Quarter Outlook (with major analytical insights)

Main business trajectory and revenue mechanics

Crinetics Pharmaceuticals Inc.’s main reported business in the dataset is licensing revenue recognition, which is slated to contribute the majority of recognized revenue in the current quarter. The forecast for revenue at $4.74 million indicates sizable recognition relative to the prior quarter’s $0.14 million, pointing to timing-related recognition of license or collaboration milestones rather than recurring product sales. Because gross margin and net margin details are not available, the focus shifts to operating line items: EBIT is expected at -$133.09 million and EPS at -$1.37, which reflects sustained R&D and SG&A investment typical of late-stage clinical programs. Investors should anticipate that fluctuations in quarterly revenue will likely reflect accounting recognition schedules more than structural demand changes, which tempers conclusions drawn solely from the topline growth rate.

Most promising growth segment

The dataset identifies recognized license revenue as the largest near-term growth contributor, with the current-quarter forecast effectively all revenue derived from this segment. With an estimate of $4.74 million and a year-over-year growth projection of 555%, this segment exhibits high volatility as it depends on contract milestones and billing schedules. While this provides near-term uplift to revenue, its durability is uncertain, and visibility is typically limited to disclosed agreements. The strategic implication is that forecasting beyond the quarter requires clarity on pending milestones, which would influence both cash inflows and the cadence of recognized revenue.

Key stock price drivers this quarter

Share performance around the print is likely to react more to pipeline updates, cost trajectory, and any licensing developments than to the nominal revenue figure, given the expected negative EBIT and EPS. A miss or beat on EPS relative to the -$1.37 estimate could drive near-term volatility, especially if operating expenses diverge from modeled assumptions. Additionally, any updates to collaboration or licensing arrangements can materially affect revenue recognition timing, with implications for cash runway perceptions and valuation multiples. Absent detailed disclosed gross margin figures, attention will likely concentrate on operating expense guidance, clinical milestones, and commentary about upcoming catalysts.

Analyst Opinions

Across collected views since January 1, 2026 through February 19, 2026, institutional sentiment skews bullish. Buy ratings were reiterated or maintained by Cantor Fitzgerald (price target $90.00), H.C. Wainwright (price target $81.00), Morgan Stanley (price target $77.00), Robert W. Baird (price target $62.00), Stifel Nicolaus (price target $58.00), and Piper Sandler (price target $97.00), while Goldman Sachs maintained a Hold rating with a $40.00 target. The ratio of bullish versus bearish/neutral opinions is 6:1 in favor of bullish views, and commentary centers on anticipated progress in the company’s clinical programs and outlook for strategic collaborations. The majority view contends that while operating losses persist, the company’s expected revenue recognition and pipeline updates should underpin investor confidence. Analysts emphasize that near-term earnings are less indicative of intrinsic value than the trajectory of clinical catalysts, with Cantor Fitzgerald and Piper Sandler highlighting potential milestones that could de-risk the development path and support valuation resilience over the coming quarters.